First US base editing trial on the way after FDA thumbs up

Gene editing company Verve Therapeutics (Nasdaq: VERV) has been cleared by the US regulator to go ahead with what will be the first in-human base editing study in the country,

The US Food and Drug Administration, which placed a hold on clinical work late last year, has taken a cautious stance when it comes to new gene technologies such as base editing.

The approach combines components from the more familiar CRISPR system, together with enzymes to directly install mutations into DNA.